about
Products of metabolic activation of the antitumor drug ledakrin (nitracrine) in vitro.CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells.Influence of temperature and interactions with ligands on dissociation of dsDNA and ligand-dsDNA complexes of various types of binding. An electrochemical study.Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10Novel resveratrol-based substrates for human hepatic, renal, and intestinal UDP-glucuronosyltransferasesRevision of biological methods for determination of EDC presence and their endocrine potential.The overexpression of CPR and P450 3A4 in pancreatic cancer cells changes the metabolic profile and increases the cytotoxicity and pro-apoptotic activity of acridine antitumor agent, C-1748.The role of glucuronidation in drug resistance.CYP3A4-dependent cellular response does not relate to CYP3A4-catalysed metabolites of C-1748 and C-1305 acridine antitumor agents in HepG2 cells.Progress in targeting tumor cells by using drug-magnetic nanoparticles conjugate.Relationship between volatile organohalogen compounds in drinking water and human urine in Poland.Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305.Electroanalytical and spectroscopic procedures for examination of interactions between double stranded DNA and intercalating drugs.Improved cytotoxicity and preserved level of cell death induced in colon cancer cells by doxorubicin after its conjugation with iron-oxide magnetic nanoparticles.Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia.Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.Phase I and phase II metabolism simulation of antitumor-active 2-hydroxyacridinone with electrochemistry coupled on-line with mass spectrometryThe synthesis and antitumor activity of N-glycosyl derivatives of daunorubicinEnzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNAThe relevance of enzymatic oxidation by horseradish peroxidase to antitumour potency of imidazoacridinone derivativesMolecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311Electrooxidation of dissolved dsDNA backed by in situ UV-Vis spectroscopyDiminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cellsThe imidazoacridinone antitumor drug, C-1311, is metabolized by flavin monooxygenases but not by cytochrome P450sFlavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cellsModulation of UDP-glucuronidation by acridinone antitumor agents C-1305 and C-1311 in HepG2 and HT29 cell lines, despite slight impact in noncellular systemsStable nanoconjugates of transferrin with alloyed quaternary nanocrystals Ag-In-Zn-S as a biological entity for tumor recognition
P50
Q31915712-54969199-8EF2-4CDD-A6B3-0E49160C4FFDQ33823679-6DB79EE2-72A1-44E8-B0A9-2F4AB175C5E0Q34148697-779909BA-2ACB-486C-9F13-BE12094AE749Q36174250-7EBABC12-F6EE-4899-9540-42E3D7FDFAC6Q37727667-37D4776F-B1B5-48E2-B86C-D093AC8156B7Q38409324-DA58E878-C1D8-4F65-8506-C54628A724B7Q38699221-37630B55-84AA-477A-8A4D-39A4D03A8655Q38710791-138E5D2D-8ABA-4838-B6CE-3FDB09AAE4FAQ38988914-5C2D165B-4553-4851-9F9E-FBF6BB1D7CECQ39209053-B080D9A8-A49F-400E-AA9B-122980476AC2Q44593753-F33D282F-C1AD-4054-9F39-C05DABD8101EQ46587852-9F6BE3A1-AFD6-4B3D-981E-87CC034E100BQ46947125-F03D979C-F694-426D-9F7A-0E53E96DC154Q50876445-F475D62F-836C-4353-8FB7-66198BB26B48Q50979361-AFFCF858-BEB6-461E-A5B9-BB2AF4822414Q53115561-754B84A2-9F03-436C-88E8-A0005EBC2183Q57286812-6F8A90D4-7579-4E89-8479-54EDB78A86C5Q70675258-9DE974D6-65C5-4086-9CC9-EBD2801BC6EFQ73667146-C95F23B6-92E3-45B6-872B-AC63C3D1B7E9Q77561034-0C26A38B-7470-4FD5-AD14-6255E10EB8F3Q79175571-C9DD8723-BB17-4CBC-BDE0-C0A274A05EC5Q80098581-40AA25FB-4CAC-4EC2-BDFC-93C4ABA7A536Q83830975-8B9883A2-C378-405E-9A55-AECA6EC51E56Q84069151-D22AF4FA-DEE0-49F6-AE3C-C4CB1E29DE4AQ84805903-3EB3B1D5-67B9-4203-96B2-3823DB34F0CBQ88343146-9E357C3E-E462-4EA4-AC3D-2D0122431302Q89769536-58A3CBB1-3B58-45F6-BC86-93DDC4DD205D
P50
description
Pools onderzoekster
@nl
hulumtuese
@sq
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Zofia Mazerska
@ast
Zofia Mazerska
@ca
Zofia Mazerska
@cs
Zofia Mazerska
@en
Zofia Mazerska
@es
Zofia Mazerska
@gl
Zofia Mazerska
@hr
Zofia Mazerska
@hsb
Zofia Mazerska
@it
Zofia Mazerska
@nl
type
label
Zofia Mazerska
@ast
Zofia Mazerska
@ca
Zofia Mazerska
@cs
Zofia Mazerska
@en
Zofia Mazerska
@es
Zofia Mazerska
@gl
Zofia Mazerska
@hr
Zofia Mazerska
@hsb
Zofia Mazerska
@it
Zofia Mazerska
@nl
prefLabel
Zofia Mazerska
@ast
Zofia Mazerska
@ca
Zofia Mazerska
@cs
Zofia Mazerska
@en
Zofia Mazerska
@es
Zofia Mazerska
@gl
Zofia Mazerska
@hr
Zofia Mazerska
@hsb
Zofia Mazerska
@it
Zofia Mazerska
@nl
P1053
O-7424-2018
P106
P1153
6701576959
P1412
P1559
Zofia Mazerska
@pl
P21
P214
268144782721750928551
P27
P31
P496
0000-0003-0115-8443
P735
P7859
viaf-268144782721750928551